Postherpetic NeuralgiaPhase 2NCT06708416
A Study of ONO-1110 in Patients With Postherpetic Neuralgia
A Phase 2 study testing ONO-1110 in people with Postherpetic Neuralgia, run by Ono Pharmaceutical Co., Ltd. at 31 sites in Japan.
Trial summary
To evaluate the efficacy and safety of ONO-1110 in Japanese patients with postherpetic neuralgia Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Postherpetic Neuralgia
- What is being tested?
- ONO-1110
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 142 participants
- Where
- 31 sitesJapan
- Study dates
- 12 Feb 2025to 11 May 2026
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Japanese (both sexes)
- Age (at the time of informed consent): 18 years and older
- Outpatient
- Patients with persistent pain ≥3 months (90 days) after the onset of herpes zoster
- Patients who are considered capable of understanding the study procedures and completing the pain diary and questionnaires appropriately by the investigator (sub-investigator)
Who cannot join
- Patients who previously underwent neurodestruction or neurosurgical therapy for PHN
- Patients with pain other than PHN that may affect assessments in this study
- Patients with any skin condition related to the site of herpes zoster that may affect assessments in this study
- Patients with a past history of or concurrent neurologic diseases that may affect assessments in this study
- Patients with concurrent psychiatric diseases that may affect assessments in this study
Trial locations and contacts
31 sites in 1 country.
31 sites in 1 country
Japan31 sites
Kamezawa Clinic
Aichi
Kimura Clinic
Aichi
Fukuoka Tokushukai Hospital
Fukuoka
Southern Tohoku General Hospital
Fukushima
Central Japan International Medical Center
Gifu
National Hospital Organization Kure Medical Center
Hiroshima
National Hospital Organization Hokkaido Medical Center
Hokkaido
Nishinomiya Municipal Central Hospital
Hyōgo
Mito Saiseikai General Hospital
Ibaraki
Kawasaki Municipal Hospital
Kanagawa
Konan Hidamari Pain Clinic
Kanagawa
Nomura Dermatology Clinic
Kanagawa
Tai Clinic
Kanagawa
Yokohama City Minato Red Cross Hospital
Kanagawa
Junwakai Memorial Hospital
Miyazaki
Medical Corporation Toyama Dermatology
Miyazaki
Medical Corporation Fujigaki Clinic
Ōita
Yuaikai Tomishiro Chuo Hospital
Okinawa
Morimoto Clinic
Osaka
Osaka Medical and Pharmaceutical University Hospital
Osaka
Osaka Metropolitan University Hospital
Osaka
Chutoen General Medical Center
Shizuoka
Shizuoka Rehabili Pain Clinic
Shizuoka
Fukuuchi Pain Clinic
Tokyo
Fukuwa Clinic
Tokyo
Futaki Skin Care Clinic
Tokyo
Juntendo University Hospital
Tokyo
Mitaka Pain Clinic
Tokyo
Nishiogi Pain Clinic
Tokyo
Tokyo-Eki Center-Building Clinic
Tokyo
Yamanashi Prefectural Central Hospital
Yamanashi
About this study
Official title: A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Postherpetic Neuralgia
To evaluate the efficacy and safety of ONO-1110 in Japanese patients with postherpetic neuralgia
- Conditions
- Postherpetic Neuralgia
- Being tested
- ONO-1110, Placebo
- Keywords
- ONO-1110, ONO-1110-04, Postherpetic Neuralgia, PHN
- Medical subject headings
- Neuralgia, Postherpetic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ONO-1110Drug
ONO-1110 tablets once a day
PlaceboDrug
Placebo tablets once daily
| Study group | Role | What they receive |
|---|---|---|
| ONO-1110 | Experimental | ONO-1110 tablets once a day Receives: Drug: ONO-1110 |
| Placebo | Placebo comparator | Placebo tablets once daily Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in weekly mean of average pain score (last 7-day mean of past 24-hour average pain scores [NRS] in the pain diary) from baseline to Week 8 of the treatment period
Measured: Up to 15 weeks
Adverse Events
Measured: Up to 15 weeks
Secondary outcomes (9)
Change in weekly mean of average pain score from baseline to each week
Measured: Up to 15 weeks
30%- and 50%-responder rates based on the weekly mean of average pain score (proportions of participants whose weekly mean of average pain score has decreased by 30% and 50% from baseline, respectively)
Measured: Up to 15 weeks
Change in weekly mean of worst pain score (last 7-day mean of past 24-hour worst pain scores [NRS] in the pain diary) from baseline to each week
Measured: Up to 15 weeks
30%- and 50%-responder rates based on the weekly mean of worst pain score (proportions of participants whose weekly mean of worst pain score has decreased by 30% and 50% from baseline, respectively)
Measured: Up to 15 weeks
Change in Brief pain inventory-short form (BPI-SF) score from baseline
Measured: Up to 15 weeks
Change in Short Form McGill Pain Questionnaire-2 (SF-MPQ-2) score from baseline
Measured: Up to 15 weeks
Patient Global Impression of Change (PGIC) score
Measured: Up to 15 weeks
Change in Hospital Anxiety and Depression Scale (HADS) score from baseline
Measured: Up to 15 weeks
Plasma ONO-1110 concentrations
Measured: Up to 15 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Nov 2024
- Study start12 Feb 2025
- Primary completion11 May 2026
- Study completion11 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postherpetic NeuralgiaStudies of the same condition, open and under way.
- More trials run by Ono Pharmaceutical Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 142 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Project Leader, Study director, Ono Pharmaceutical Co., Ltd.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06708416
- Sponsor's protocol ID
- ONO-1110-04
- Other IDs
- jRCT2031240504
- Status last verified
- Jul 2026
- First submitted
- 24 Nov 2024
- Last updated
- 15 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Postherpetic Neuralgia
- ClinicalTrials.gov ID
- NCT06708416
- Acronym / sponsor ID
- ONO-1110-04
- Conditions
- Postherpetic Neuralgia
- Keywords
- ONO-1110, ONO-1110-04, Postherpetic Neuralgia, PHN
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 142 participants (actual)
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 12 Feb 2025 (actual)
- Primary completion
- 11 May 2026 (actual)
- Study completion
- 11 May 2026 (actual)
- First posted
- 27 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the efficacy and safety of ONO-1110 in Japanese patients with postherpetic neuralgia
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ONO-1110 | Experimental | Drug: ONO-1110ONO-1110 tablets once a day |
| Placebo | Placebo comparator | Drug: PlaceboPlacebo tablets once daily |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Japanese (both sexes)
- Age (at the time of informed consent): 18 years and older
- Outpatient
- Patients with persistent pain ≥3 months (90 days) after the onset of herpes zoster
- Patients who are considered capable of understanding the study procedures and completing the pain diary and questionnaires appropriately by the investigator (sub-investigator)
Key exclusion criteria (5 listed)
- Patients who previously underwent neurodestruction or neurosurgical therapy for PHN
- Patients with pain other than PHN that may affect assessments in this study
- Patients with any skin condition related to the site of herpes zoster that may affect assessments in this study
- Patients with a past history of or concurrent neurologic diseases that may affect assessments in this study
- Patients with concurrent psychiatric diseases that may affect assessments in this study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ONO-1110ONO-1110 tablets once a day | Drug | ONO-1110 |
| PlaceboPlacebo tablets once daily | Drug | Placebo |
Primary outcome
Change in weekly mean of average pain score (last 7-day mean of past 24-hour average pain scores [NRS] in the pain diary) from baseline to Week 8 of the treatment period
Time frame: Up to 15 weeks
Adverse Events
Time frame: Up to 15 weeks
9 secondary outcomes
Change in weekly mean of average pain score from baseline to each week
Time frame: Up to 15 weeks
30%- and 50%-responder rates based on the weekly mean of average pain score (proportions of participants whose weekly mean of average pain score has decreased by 30% and 50% from baseline, respectively)
Time frame: Up to 15 weeks
Change in weekly mean of worst pain score (last 7-day mean of past 24-hour worst pain scores [NRS] in the pain diary) from baseline to each week
Time frame: Up to 15 weeks
30%- and 50%-responder rates based on the weekly mean of worst pain score (proportions of participants whose weekly mean of worst pain score has decreased by 30% and 50% from baseline, respectively)
Time frame: Up to 15 weeks
Change in Brief pain inventory-short form (BPI-SF) score from baseline
Time frame: Up to 15 weeks
Change in Short Form McGill Pain Questionnaire-2 (SF-MPQ-2) score from baseline
Time frame: Up to 15 weeks
Patient Global Impression of Change (PGIC) score
Time frame: Up to 15 weeks
Change in Hospital Anxiety and Depression Scale (HADS) score from baseline
Time frame: Up to 15 weeks
Plasma ONO-1110 concentrations
Time frame: Up to 15 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Postherpetic Neuralgia
Not yet recruitingPhase 1
Simultaneous Engagement of Networks for Alleviating Pain (SENAP)
Neuropathic Pain, Postherpetic Neuralgia
Active, not recruiting
Transcranial Magnetic Stimulation for Chronic Neuropathic Pain
Chronic Neuropathic Pain, Post-Stroke Pain
Active, not recruitingObservational study
Obesity and Obesity-Related Factors and Risk of Herpes Zoster (Shingles) and Postherpetic Neuralgia
Herpes Zoster (HZ)
Recruiting
The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster
Herpes Zoster, Pain
Not yet recruiting
Efficacy and Safety of Intravenous Dexamethasone Palmitate Treatments in Acute and Subacute Herpes Zoster Pain
Herpes Zoster Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Project Leader study director
Ono Pharmaceutical Co., Ltd.
31 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing ONO-1110 in people with Postherpetic Neuralgia, run by Ono Pharmaceutical Co., Ltd. at 31 sites in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 31 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in weekly mean of average pain score (last 7-day mean of past 24-hour average pain scores [NRS] in the pain diary) from baseline to Week 8 of the treatment period (time frame: Up to 15 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2026.